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Antimicrobial peptides, also known as host defense peptides, have recently emerged as
a promising new category of therapeutic agents for the treatment of infectious diseases.
This study evaluated the preclinical in vitro, ex vivo, and in vivo antimicrobial activity, as
well as the potential to cause skin irritation, of human kininogen-derived antimicrobial
peptide DPK-060 in different formulations designed for topical delivery. We found that
DPK-060 formulated in acetate buffer or poloxamer gel caused a marked reduction of
bacterial counts of Staphylococcus aureus in vitro (minimum microbicidal concentration
<5µg/ml). We also found that DPK-060 in poloxamer gel significantly suppressed
microbial survival in an ex vivo wound infection model using pig skin and in an in vivo
mouse model of surgical site infection (≥99 or ≥94% reduction in bacterial counts
was achieved with 1% DPK-060 at 4 h post-treatment, respectively). Encapsulation of
DPK-060 in different types of lipid nanocapsules or cubosomes did not improve the
bactericidal potential of the peptide under the applied test conditions. No reduction in cell
viability was observed in response to administration of DPK-060 in any of the formulations
tested. In conclusion, the present study confirms that DPK-060 has the potential to be
an effective and safe drug candidate for the topical treatment of microbial infections;
however, adsorption of the peptide to nanocarriers failed to show any additional benefits.
Keywords: antimicrobial peptides, DPK-060, skin infections, lipid nanocapsules, cubosomes
INTRODUCTION
The rapidly increasing resistance toward conventional antibiotics has accelerated research efforts
to identify new and non-conventional anti-infective therapies (Czaplewski et al., 2016). One
category of the recently emerged novel drug candidates for the treatment of infectious disease
are antimicrobial peptides (AMPs), also known as host defense peptides (Mahlapuu et al., 2016).
AMPs are low mass and generally positively charged peptides, which display a large structural
and functional diversity. Most AMPs have the ability to kill microbial pathogens directly, whereas
others act indirectly via immunomodulatory actions (Fjell et al., 2011). Importantly, AMPs
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are generally considered to be less prone to microbial resistance
compared with conventional antibiotics (Andersson et al., 2016).
A number of AMPs have already been introduced into the
market, and additional AMPs are currently being tested in clinical
trials (Fox, 2013). In spite of these encouraging examples, there is
still a considerable discrepancy between the extensive range of
AMPs claimed as potent drug candidates in the patents or related
scientific literature and the relatively few reported outcomes of
the clinical trials (Kosikowska and Lesner, 2016).
The implementation of innovative formulation strategies is
one of the factors, which is expected to accelerate the translation
of preclinical candidate AMPs into successful clinical products.
Notably, the use of nanocarriers for the delivery of AMPs has
recently emerged as one area of interest, since nanoparticles
provide unique advantages due to their large surface area
for adsorption/encapsulation of AMPs and prevention of self-
aggregation of the peptides (Eckert, 2011; Sandreschi et al., 2016;
Nordström and Malmsten, 2017).
One of the AMPs, where intense preclinical and clinical
research has been conducted in the past, is DPK-060 (also known
as GKH17-WWW), which was developed for the treatment of
skin infections. DPK-060 is a chemically synthesized peptide
structurally derived from human protein kininogen, where
three tryptophan residues have been added to the C-terminal
end of the endogenous 17-amino acid sequence (Schmidtchen
et al., 2009). In comparison to its endogenous analog, this
addition enhances the ability of DPK-060 to withstand enzymatic
degradation by infection-affiliated proteases, without any signs
of aggravated cytotoxicity (Schmidtchen et al., 2009). DPK-
060 exhibits a potent broad-spectrum antimicrobial activity in
vitro against both Gram-positive and Gram-negative bacteria
including methicillin-resistant Staphylococcus aureus (MRSA;
Boge et al., 2017; Nordström et al., 2018). The safety and
efficacy of 1% DPK-060 in a polyethylene glycol (PEG)-based
ointment has been studied in a clinical phase II trial in the
treatment of skin infections in atopic dermatitis patients. The
results of this trial revealed that DPK-060 1% ointment was well
tolerated by the subjects and significantly reduced the microbial
density in eczematous lesions after 14 days with twice daily
application compared with placebo (ClinicalTrials.gov Identifier:
NCT01522391; EudraCT: 2007-007103-32).
This study applies new formulation strategies including
different classes of nanocarriers to formulate DPK-060 for topical
delivery, and characterizes these different dose formulations in
terms of preclinical in vitro, ex vivo, and in vivo antimicrobial




molecular weight 2.5 kDa, net charge +8.5 at pH 5.5, random
coil secondary structure) was produced using Fmoc solid
Abbreviations:AMP, antimicrobial peptide; LCNP, liquid crystalline nanoparticle;
LNC, lipid nanocapsule: ML-LNC, monolaurin lipid nanocapsule; MMC,
minimum microbicidal concentration.
phase technology at Bachem AG, Bubendorf, Switzerland.
The peptide was identified by electrospray ionization mass
spectrometry and the purity was assessed by HPLC. The purity
of the peptide used in all studies was 98.5%. Bactroban, 2%
ointment (GlaxoSmithKline, Brent-ford, UK) was used as
control antibiotics in in vivo studies.
Formulations
DPK-060 was first associated with the nanocarriers, whereupon
the DPK-060-loaded nanocarriers were dispersed into an in situ
gelling poloxamer formulation (Table 1). The nanocarriers were
characterized in terms of size (Z-average particle diameter) and
polydispersity index by dynamic light scattering prior to use
(Boge et al., 2016; Umerska et al., 2016b). The chemical stability
of the peptide in all formulations investigated has been verified
(assay by HPLC >95%).
Poloxamer Gel Formulation
Poloxamer 407 (Kolliphor R© P407; kindly provided by BASF,
Ludwigshafen, Germany) and methyl paraben (Fluka, Buchs,
Switzerland) were dissolved in 20mM acetate buffer pH 5.5 in
an ice bath for 1–2 h until the polymer was completely dissolved
(23 wt% poloxamer 407 and 0.03 wt% methyl paraben). For
formulations containing DPK-060 without a nanocarrier, DPK-
060 was first dissolved in acetate buffer and then added to
the polymer solution while stirring. The final concentrations of
poloxamer 407 and methyl paraben were 17 wt% and 0.02 wt%,
respectively; the final concentrations of DPK-060 were 0.25 wt%,
0.5 wt%, and 1.0 wt%, corresponding to approximately 1.0mM,
2.0mM, and 4.0mM, respectively.
Formulations With Lipid Nanocapsules
Lipid nanocapsules (LNCs) were prepared as described
previously (Valcourt et al., 2016; Umerska et al., 2017).
LNCs were composed of lecithin (Lipoid R© S75–3; kindly
provided by Lipoïd Gmbh, Ludwigshafen, Germany), medium
chain triglycerides (Labrafac R© WL1349; kindly provided
by Gattefossé S.A., Saint-Priest, France), and macrogol 15
hydroxystearate (Kolliphor R© HS 15; BASF, Ludwigshafen,
Germany). Briefly, lecithin (75mg), triglycerides (846mg),
macrogol 15 hydroxystearate (1,028mg), sodium chloride
(90mg), and 20mM acetate buffer pH 5.5 (3ml) were mixed and
homogenized under magnetic stirring. The resulting emulsion
was then heated to 90◦C and cooled to 60◦C 2 times, and then
heated to 90◦C and cooled to 78◦C, to obtain reversible emulsion
phase inversions. After the temperature of 78◦C (the phase
inversion temperature) had been reached, an irreversible shock
was induced by a rapid dilution with 12.5ml 4◦C purified water
to reach room temperature. Formonolaurin (ML)-LNCs, lecithin
was replaced by monolaurin (Sigma Aldrich, Lyon, France);
monolaurin (300mg), triglycerides (930mg), macrogol 15
hydroxystearate (770mg), sodium chloride (90mg), and 20mM
acetate buffer pH 5.5 (3ml) were mixed. The resulting emulsion
was then heated to 60◦C and cooled to 20◦C 2 times, and then
heated to 60◦C and cooled to 37◦C. After the temperature of
37◦C (the phase inversion temperature) had been reached, the
dispersion was rapidly diluted with 20◦C purified water to a
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FIGURE 1 | Schematic presentation of the experimental design of the study. LNC/ML-LNC particles were constructed and DPK-060 was adsorbed to the particle
surface; DPK060-loaded LNCs/ML-LNCs were then added to the poloxamer gel. A cubic liquid crystalline gel was formed by mixing glycerol monooleate with
DPK-060; cubosomes were then prepared by dispersing the cubic gel in poloxamer solution. In most experiments, DPK-060 dissolved in poloxamer gel was included
as a reference group. The in vitro/ex vivo/in vivo antimicrobial efficacy of the formulations was characterized, and the release profile and skin irritancy were assessed.
GMO, glycerol monooleate.
volume of 10ml. The particle size of the LNCs and ML-LNCs
was in the range of 50–80 nm and 30–45 nm, respectively, with a
polydispersity index <0.1.
To prepare peptide-loaded LNCs/ML-LNCs, the
LNCs/ML-LNC dispersions were mixed with 160 mg/g (16
wt%) DPK-060 in acetate buffer at a ratio of 3:1 LNCs/ML-
LNCs:DPK-060 solution, for 2–3 h [sufficient for peptide
molecules to achieve a dynamic equilibrium between the LNCs
and the surrounding medium (Umerska et al., 2016b)], resulting
in a peptide concentration of 40 mg/g (4 wt%).
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TABLE 1 | Formulation properties.
Formulation Poloxamer
407 (wt%)
Nanocarrier Nanocarrier components Particle size,
nanocarrier (nm)
Peptide loading
Poloxamer gel 17 – – – –
LNCs in
poloxamer gel













3 Cubosomes Glycerol monooleate 200–300 Loading during
nanocarrier formation
Finally, the DPK-060-loaded LNCs/ML-LNCs were added
to the poloxamer gel in a 1:3 ratio while stirring at slow
speed (300–500 rpm) in an ice bath for 60min, which resulted
in a homogenous viscous liquid. The final concentration of
poloxamer 407 was 17 wt%; the final concentrations of DPK-
060 were 0.25 wt%, 0.5 wt%, and 1.0 wt%, corresponding to
approximately 1.0mM, 2.0mM, and 4.0mM, respectively. The
final concentrations of LNCs/ML-LNCs were five-fold higher
than the DPK-060-concentrations, i.e., 1.25 wt%, 2.5 wt%, and
5.0 wt%.
The adsorption efficiencies of DPK-060 in LNCs and
ML-LNCs were 33.8 ± 3.5% and 33 ± 5%–42 ± 2%,
respectively, (manuscript by Matougui et al., in preparation;
Rozenbaum et al., 2019).
Formulations With Cubosomes
Liquid crystalline nanoparticles (LCNPs) with cubic phase
structure, i.e., cubosomes, were prepared as described previously
(Boge et al., 2016). In brief, molten glycerol monooleate
(Capmul-90 EP/NF; kindly provided by Abitec Corp., Columbus,
OH) at 50◦C was mixed with DPK-060 (at 28, 56, or 111
mg/ml) in acetate buffer (20mM pH 5.5) at 22◦C to reach a
final concentration of 70:30 wt% glycerol monooleate:buffer with
DPK-060 and was then allowed to equilibrate for 2 days at 22◦C
to form a cubic gel. Typical weights of prepared liquid crystalline
gels were 1.7 g. Cubosomes were formed by first dispersing
1.5 g liquid crystalline gel in 3.5 g 20mM acetate buffer pH 5.5
containing 3 wt% poloxamer 407 for 1min using a Ultra-Turrax
high-shear mixer (IKA T25, Staufen, Germany) with a diameter
of 8mm at 15,000 rpm, followed by sonication using a Vibracell
Probe Sonicator (Sonics and Materials, Inc., Newtown, CT) with
a 6mm probe operating in pulse mode (3 s sonication followed
by 7 s break) over a period of 10min. This resulted in cubosomes
in the size range of 200–300 nm with a polydispersity index
about 0.3. The preparation of cubosomes using the shearing
and sonication was shown not to affect the chemical stability
of DPK-060 as investigated by HPLC. The cubic structures of
the particles were verified by small angle x-ray scattering (Boge
et al., 2016). The final concentration of poloxamer 407 was
3% (higher concentrations influence the phase properties of the
LCNPs); the final concentrations of DPK-060 were 0.25, 0.5 and
1.0 wt% (corresponding to approximately 1.0, 2.0, and 4.0mM,
respectively); the final concentration of cubosomes was 30 wt%
in all formulations. Methyl paraben (0.02 wt%) was added to the
final dispersions.
Loading of DPK-060 into the cubic liquid crystalline gel
followed by dispersion, as was used in this study, has been
previously shown to result in a high peptide entrapment of 50–
70%, whereas post-loading of cubosomes results in only 10–20%
of DPK-060 being associated with the particles at the condition
of low ionic strength (Boge et al., 2016, 2017). Therefore, the
method of DPK-060 loading into the cubic liquid crystalline gel,
which results in highest peptide encapsulation efficiency, was
selected in this study.
Assessment of Antimicrobial Activity
in vitro
Minimum Microbicidal Concentration Assay
The microbicidal effect of DPK-060 in different formulations was
assessed against Staphylococcus aureus (ATCC 29213; American
Type Culture Collection, Manassas, VA) using a minimum
microbicidal concentration (MMC) assay as described (Björn
et al., 2016). The MMC assay was performed in 100× diluted
brain-heart infusion broth (BHIdil; Håversen et al., 2000, 2010;
Kondori et al., 2011). Theminimal peptide concentration causing
>99.6% reduction of microorganisms was defined as the MMC.
Time-Kill Assay
Time-kill assay against S. aureus (ATCC 29213) was performed
as previously described (Boge et al., 2017) incubating 20 µl of a
bacterial suspension (∼1.8 × 107 CFU/ml) with 0.25ml of each
test item and 1.48ml of BHIdil.
In vitro Release
Release of DPK-060 from the different formulations was
monitored through dialysis as described previously (Boge et al.,
2017) using a Float-A-Lyzer R© G2 dialysis device with 100 kDa
molecular weight cut-off (Spectrum Laboratories Inc., Rancho
Dominques, CA). The dialysis experiments were performed
at 0, 7, and 14 days of storage of the formulations at room
temperature. The samples were allowed to dialyze in 20mM
acetate buffer pH 5.5 for 24 h at room temperature, whereupon a
450 µl aliquot was removed from the receptor side/dialysate and
diluted with 50 µl formic acid. The concentration of DPK-060
was then analyzed in duplicate samples by UHPLC using gradient
elution and UV detection at 214 nm (Boge et al., 2016). The
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samples were analyzed on an Acquity UHPLC system (Waters
corp, Milford, MA). The injection volume was 5 µl and the
sampler was kept at 5◦C. The mobile phases were; A: acetonitrile
and purified water with 0.1% TFA and 50mM NaCl 5/95 and
B: acetonitrile and purified water with 0.1% TFA and 50mM
NaCl 70/30. The separation was performed by gradient elution
starting from 26% phase B (kept constant for 1.5min) increased
to 35% phase B in 11min (kept constant for 3min), followed by a
wash step at 100% phase B (1.1min) and an equilibration step
at 26% phase B (3.4min). The flow rate was 0.25 ml/min and
the column was kept at 55◦C. DPK-060 was detected at 214 nm
and quantified by peak area, quantitative dilutions, and external
calibration in the range of 0.01–0.25 mg/ml.
The release of DPK-060 from the poloxamer gel formulation
with and without LNCs was also investigated by Franz diffusion
cell studies. Aluminum oxide membranes (Anodisc, 25mm,
pore size 0.02µm, Whatman, GE Healthcare, Buckinghamshire,
UK) were mounted in Franz diffusion cells (PermeGear Inc.,
Hellertown, PA) with a 0.64 mm2 surface area and receptor
volume of 5ml. 10mM phosphate buffer pH 7.4, 0.8% NaCl was
used as receptor medium and allowed to equilibrate at 32◦C for
30min prior to the application of 100µl formulation to the donor
compartment. Aliquots of 200 µl were collected over the period
of 36 h and analyzed by UHPLC as described above.
In vitro EpiDerm Skin Irritation Test
The effect of DPK-060 in different formulations on cell viability
was determined in compliance with OECD Test Guideline 439
by using the EpiDerm Skin Irritation Test (EPI-200-SIT; MatTek
In Vitro Life Science Laboratories, Bratislava, Slovakia) according
to manufacturer’s instruction.
Ex vivoWound Infection Model Using Pig
Skin
The ability of DPK-060 in different formulations to reduce
colonization of S. aureus (ATCC 29213) was evaluated in an
ex vivo wound infection model using pig skin as previously
described (Björn et al., 2016).
Mouse Model of Surgical Site Infection
The injury, infection with S. aureus (ATCC 29213), and sample
collection/analysis for surgical site infection model were carried
out in female mice of CD1 strain as previously described
(Håkansson et al., 2014). In vivo experiments were performed
after prior approval from the local Ethics Committee for Animal
Studies at the Administrative Court of Appeals in Gothenburg,
Sweden (approval number: Dnr 26-2015).
The treatment-related systemic toxicity was assessed by
observing general behavior and clinical signs including body
posture, central excitation, mood, and motor activity. The local
tolerability was assessed by observing incidence of erythema
and oedema.
The doses of DPK-060 used in ex vivo and in vivo studies refer
to the total concentrations of DPK-060 in the formulation and
do not take into consideration the potential differences in the
release pattern.
Statistical Analysis
Statistical significance between the groups was calculated using
one-way ANOVA followed by LSD post-hoc test, with a value
of P <0.05 considered statistically significant. The statistical
analyses were performed using SPSS Statistics (v24; IBM
Corporation, Armonk, NY).
RESULTS
In vitro Antimicrobial Potency
The MMC for DPK-060 in acetate buffer or when formulated
with different nanocarriers in poloxamer gel was in the range of
1–5µg/ml (Table 2). No antibacterial activity was detected when
these formulations were tested without any DPK-060 added (data
not shown).
DPK-060 in acetate buffer or in poloxamer gel displayed
bactericidal effect in time-kill assay at concentrations equal or
higher than 2µg/ml with a significant reduction in the CFU
numbers detected after 3 h of incubation (Figures 2A,B). DPK-
060-loaded LNCs and ML-LNCs in poloxamer gel inhibited
bacterial growth to the extent similar to that observed with DPK-
060 in acetate buffer/poloxamer gel (Figures 2C,D). DPK-060-
loaded cubosomes in poloxamer solution were less effective: the
bactericidal effect was observed only at the highest concentration
tested (8µg/ml; Figure 2E). Nanocarrier gels without DPK-060
did not display any significant inhibition in bacterial growth
(Figures 2C–E).
In vitro Release
The release of the peptide from DPK-060-loaded LNCs and
cubosomes in poloxamer gel was first investigated by dialysis
method. The results reveal that after 24 h of incubation, 100% of
DPK-060 was released from the LNCs in poloxamer gel as well
as from the poloxamer gel without any nanocarriers (Figure 3).
In contrast, under these test conditions about 50–70% of DPK-
060 remained encapsulated in the cubosomes (Figure 3). Of note,
the release properties were similar comparing the formulations
analyzed directly after preparation with those stored for 7 or 14
days before the dialysis experiment (Figure 3).
The peptide release efficiency from DPK-060-loaded LNCs
in poloxamer gel was further investigated by Franz diffusion
cell studies. The results reveal identical release profile for DPK-
060 in poloxamer gel with or without encapsulation of the
TABLE 2 | MMC for DPK-060 in different formulations against S. aureus.
Test item MMC (µg/ml)
DPK-060 in acetate buffer 4.9
DPK-060 in poloxamer gel 1.2–2.4
DPK-060-loaded LNCs in poloxamer gel 2.4
DPK-060-loaded ML-LNCs in poloxamer gel 1.2
DPK-060-loaded cubosomes in poloxamer solution 4.9
The MMC test is a semiquantitative assay; the results are presented either as one
concentration value or, in case there was a variation between the repetitions, as a
concentration range.
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FIGURE 2 | Time-kill assay for DPK-060 formulated in acetate buffer (A), poloxamer gel (B), or in different nanocarriers in poloxamer gel (C–E) against S. aureus.
Data are mean ± SD (n = 3). Samples were considered as bactericidal if there was at least 3 log reduction in the CFU number compared with the starting inoculum.
peptide into LNCs: approximately 40% of DPK-060 was released
within 3 h of incubation and full release (100%) was observed at
10 h (Figure 4).
Antibacterial Effect in ex vivo and in vivo
Wound Infection Models
The antibacterial activity of DPK-060-loaded nanocarriers (0.25,
0.5, and 1.0% of DPK-060) was investigated in an ex vivo
pig skin model. The formulations were administered 2 h post-
infection with S. aureus, and the bacteria were harvested 4 h
post-treatment (Figure 5A). DPK-060 in poloxamer gel, as well
as DPK-060-loaded LNCs and ML-LNCs in poloxamer gel,
significantly reduced the bacterial survival compared with sham
(no treatment) as well as corresponding placebo (formulation
only) and the concentration of 1% DPK-060 suppressed
the bacterial survival with ≥99% vs. the sham (Figure 5A).
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FIGURE 3 | The release of DPK-060 from the formulations after different storage times (0, 7, or 14 days) investigated by dialysis method. Data are mean ± SD (n = 2).
FIGURE 4 | The release of DPK-060 investigated by Franz diffusion cell
studies. Data are mean ± SD (n = 2).
The DPK-060-loaded cubosomes in poloxamer solution also
diminished the microbial counts compared with sham/placebo;
however, the anti-infectious potency was less pronounced
compared with DPK-060-loaded LNCs/ML-LNCs (Figure 5A).
The ex vivo antimicrobial effect of selected formulations
(1.0% DPK-060 in poloxamer gel, with or without nanocarriers)
was further studied in the pig skin model after a longer
follow-up period, i.e., the bacteria were harvested 24 h after
the treatment (Figure 5B). In this setting, the bacterial
survival was significantly reduced only in wounds treated
with DPK-060 in poloxamer gel compared with corresponding
placebo (Figure 5B).
The antimicrobial effect of DPK-060-loaded nanocarriers
(0.25, 0.5, and 1.0% of DPK-060) was also studied in a murine in
vivo model of surgical site infection. In this model, a silk suture
contaminated with S. aureus was implanted into an incision
wound on the back of mice and assessment of the infection
was performed 4 h post-treatment (Figure 6). The same model
has been used previously to characterize the effect of systemic
and topical antimicrobial agents and the results observed have
closely correlated with efficacy in clinical trials with human
subjects (Mcripley and Whitney, 1976; Gisby and Bryant, 2000;
Rittenhouse et al., 2006). DPK-060 in poloxamer gel significantly
suppressed the bacterial survival compared with sham as well as
placebo (poloxamer gel) with a clear dose response relationship;
the effect of 1% DPK-060 in poloxamer gel was comparable with
the treatment with comparator 2% Bactroban (i.e., reduction
in the bacterial survival with approximately 95% vs. the sham,
Figure 6). Notably, DPK-060-loaded LNCs and cubosomes
in poloxamer gel displayed minor/no antimicrobial effect in
this model and no obvious dose response relationship was
observed (Figure 6).
Safety and Local Tolerability
In connection to the local application of the formulations in the
surgical site infection model in mice, with or without DPK-060,
no systemic toxicity or local tolerability concerns were visually
observed in any of the mice. According to in vitro EpiDerm
Skin Irritation Test, the test item is considered to display an
irritating potential in case the viability is reduced by >50%
of the values measured for negative control sample. All the
formulations tested, with or without DPK-060, displayed the cell
viability of ≥90% of the control sample.
DISCUSSION
The MMC results in this study corroborated the previous
findings (Schmidtchen et al., 2009; Boge et al., 2016, 2017;
Nordström et al., 2018) that human kininogen-derived peptide
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 May 2019 | Volume 9 | Article 174
Håkansson et al. Efficacy of the Antimicrobial Peptide DPK-060
FIGURE 5 | Antibacterial effect of DPK-060 formulated in poloxamer gel, or in different nanocarriers in poloxamer gel, in an ex vivo wound infection model using pig
skin. The bacterial survival was assessed 4 h (A) or 24 h (B) after the treatment. Schematic presentation of the experimental setup is shown. Data on bacterial survival
of S. aureus are mean ± SEM (n = 4–5 wounds per treatment group). ** P < 0.01 (only the comparisons with the corresponding vehicle are shown). Vh, vehicle.
DPK-060 in acetate buffer or in poloxamer gel displays an in
vitro bactericidal action against S. aureus with activities in the
micromolar range. In vitro, different AMPs including DPK-
060, when adsorbed to nanoparticles, have shown enhanced
antimicrobial activity both against planktonic bacteria and in
reducing biofilm growth (Umerska et al., 2016a, 2017; Boge et al.,
2017, 2018). In specific, antimicrobial surfactant monolaurin
used in ML-LNCs has been suggested to act in synergetic
fashion with AMPs (Umerska et al., 2016a, 2017). In contrast,
here we found that the MMC for DPK-060 formulated with
different nanocarriers was in the similar range as the MMC
for DPK-060 in acetate buffer or in poloxamer gel (1–5µg/ml).
Furthermore, in this study the DPK-060-loaded LNCs/ML-LNCs
displayed similar microbicidal effect in time-kill assay compared
with DPK-060 in acetate buffer/poloxamer gel (close-to-maximal
effect at concentrations ≥2µg/ml), whereas DPK-060-loaded
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FIGURE 6 | Antibacterial effect of DPK-060 formulated in poloxamer gel, or in different nanocarriers in poloxamer gel, in an in vivo mouse model of surgical site
infection. Schematic presentation of the experimental setup is shown. Results are presented as average relative bacterial survival (%) of S. aureus compared to sham
± SEM (n = 5 mice per each treatment group). *P < 0.05 (only the comparisons with the corresponding vehicle are shown). Vh, vehicle.
cubosomes were less effective. In summary, while this study
provides consistent evidence for the potent bactericidal action
of DPK-060 in vitro, the encapsulation of this AMP into the
nanocarriers failed to increase its antimicrobial efficacy in MMC
or time-kill assay.
In addition to in vitro investigations, we also assessed the ex
vivo and in vivo antimicrobial effect of DPK-060 in experimental
wounds in pig skin and in mice, respectively, infected with S.
aureus, which is one of the bacterial species most frequently
causing human wound infections (Cardona and Wilson, 2015).
We found that DPK-060 formulated in poloxamer gel caused
a marked and statistically significant reduction in microbial
counts with a clear dose-response relationship both ex vivo
and in vivo. These data are consistent with the results of
the previously completed clinical trial where total microbial
count as well as count of Coagulase Negative Staphylococci
(CoNS) and Gram-positive bacteria were significantly lower in
eczematous lesions of patients with atopic dermatitis after 14
days of treatment with DPK-060 1% ointment (ClinicalTrials.gov
Identifier: NCT01522391; EudraCT: 2007-007103-32).
Protection against proteolytic degradation by infection-
affiliated enzymes has earlier been reported in in vitro studies
when different AMPswere encapsulated into LNCs or cubosomes
(Boge et al., 2017, 2019), which likely relates to the fact
that the peptide is less accessible for proteolytic enzymes in
nanoparticles compared with free peptide. Nanocarriers have
also shown to enhance the skin penetration and delivery of
several active substances (Lopes et al., 2006, 2007; Rattanapak
et al., 2012; Seo et al., 2013). On the basis of these previous
findings, we hypothesized that the efficacy of DPK-060 in treating
wound infections would be enhanced in vivo when adsorbed to
nanoparticles. In contrary, we found that the antibacterial effect
of DPK-060 was diminished in a mouse model of surgical site
infection when encapsulated into LNCs or cubosomes compared
with formulating the peptide in poloxamer gel only. Notably,
the results of in vitro release experiments revealed that more
than 50% of DPK-060 remained encapsulated in the cubosomes
after 24 h of incubation; in case only the non-encapsulated “free”
peptide is giving rise to bacterial killing, this likely contributed
to the low efficacy of DPK-060-loaded cubosomes. However,
we found that the release profile for DPK-060 was similar in
poloxamer gel with or without encapsulation of the peptide into
LNCs (about 40% of DPK-060 was released within 3 h) and
the reason for low efficacy of DPK-060-loaded LNCs in vivo
remains elusive.
We did not observe any significant reduction in cell viability
with DPK-060 in any nanocarrier formulation tested when
assessed by in vitro EpiDerm Skin Irritation Test. Furthermore,
we found no visible signs of systemic toxicity or local irritation
in murine surgical site infection model in connection to the
administration of DPK-060-containing formulations. This is
consistent with the results of the clinical trial, where no serious
adverse events (SAE) were reported after dermal application of
DPK-060 in atopic dermatitis patients, whereas adverse events
(AEs) were observed at similar frequency in the DPK-060 and
placebo groups (ClinicalTrials.gov Identifier: NCT01522391).
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In conclusion, the present study confirms that DPK-060 has
the potential to be an effective and safe drug candidate for
the topical treatment of microbial infections; however, under
the applied test conditions, the adsorption of the peptide to
nanocarriers failed to show any additional benefits. Notably,
in this study, a single administration of the test formulations,
combined with a short follow-up time, was used both in ex vivo
and in vivo assessments, which is considered a limitation of the
experimental design. Repeated application over several days, and
a longer follow-up period, would closer resemble the clinically
relevant situation and may lead to different results in terms of
both efficacy and safety.
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